• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Nyxoah SA

    12/5/25 4:05:05 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care
    Get the next $NYXH alert in real time by email
    6-K 1 tm2532854d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of December 2025

     

    Commission File Number: 001-40552

     

    NYXOAH SA

    (Translation of registrant’s name into English)

     

    Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium 

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F x Form 40-F ¨

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

     

    Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

     

    Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

     

     

     

     

     

     

    Nyxoah SA

     

    On December 2, 2025, Nyxoah SA (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1.

     

    The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

     

     

     

     

    Exhibits

     

    99.1 Press Release, dated December 2, 2025

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      NYXOAH SA
         
    Date: December 5, 2025 By: /s/ John Landry
      Name: John Landry
      Title: Chief Financial Officer

     

     

     

    Get the next $NYXH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NYXH

    DatePrice TargetRatingAnalyst
    7/31/2023Buy
    H.C. Wainwright
    7/19/2023Neutral
    Robert W. Baird
    4/21/2022$30.00Outperform
    Oppenheimer
    4/6/2022$21.00Peer Perform
    Wolfe Research
    12/21/2021$47.00Overweight
    Cantor Fitzgerald
    7/28/2021$43.00Overweight
    Cantor Fitzgerald
    7/28/2021$40.00Overweight
    Piper Sandler
    7/27/2021$43.00Buy
    Stifel
    More analyst ratings

    $NYXH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Publication relating to transparency notifications

                     REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 2, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below. Robert Taub / BMI Estate On November 27, 2025, Nyxoah received a transparency notification from Robert Taub and related person BMI Estate. Based on the notification, Robert Taub (together with his controlled undertakings) holds 4,290,800 voting rights, consisting of 4,240,800 voting rights linked to securities

    12/2/25 4:30:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference

    Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – 27 November, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 1:30 p.m. (ET) the same day via webcast. A live audio webcast of the presentation will be available online at the investor relations page o

    11/27/25 4:05:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule

    Nyxoah's Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule Assignment to New Technology APC 1580 is positive news for Nyxoah's U.S. commercial rollout by strengthening hospital and ASC economics Mont-Saint-Guibert, Belgium – November 26, 2025, 7:45 am CET / 1:45 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has finalized its CY2026 Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory

    11/26/25 1:45:00 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Nyxoah S.A.

    H.C. Wainwright initiated coverage of Nyxoah S.A. with a rating of Buy

    7/31/23 8:05:01 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Robert W. Baird initiated coverage on Nyxoah S.A.

    Robert W. Baird initiated coverage of Nyxoah S.A. with a rating of Neutral

    7/19/23 7:19:37 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on Nyxoah S.A. with a new price target

    Oppenheimer initiated coverage of Nyxoah S.A. with a rating of Outperform and set a new price target of $30.00

    4/21/22 7:16:59 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    SEC Filings

    View All

    SEC Form 6-K filed by Nyxoah SA

    6-K - Nyxoah SA (0001857190) (Filer)

    12/5/25 4:05:05 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Nyxoah SA

    424B5 - Nyxoah SA (0001857190) (Filer)

    11/17/25 6:30:30 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Nyxoah SA

    6-K - Nyxoah SA (0001857190) (Filer)

    11/14/25 4:05:07 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Leadership Updates

    Live Leadership Updates

    View All

    Nyxoah Appoints John Landry as Chief Financial Officer

    Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market. Mr. Landry

    11/4/24 4:45:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Appoints Scott Holstine as Chief Commercial Officer

    Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a successful U.S. launch. Scott brings over 26 years of experience in the medical device industry with a proven track record in U.S. product launches, building and leading commercial organizations trademarked by

    7/15/24 2:00:00 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Strengthens its Executive Leadership Team

    Nyxoah Strengthens its Executive Leadership TeamFrancis Kim appointed as Chief Regulatory and Quality Officer Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah's Global Regulatory and Quality departments. Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device

    11/28/23 4:30:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Financials

    Live finance-specific insights

    View All

    Nyxoah Reports Third Quarter 2025 Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of 2025. Recent Financial and Operating Highlights Completed the first commercial implants of U.S. patients, and genera

    11/13/25 4:12:11 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025

    Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025 Mont-Saint-Guibert, Belgium – Thursday, October 30, 2025, 10:10pm CET / 5:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Thursday, November 13, 2025. Company management will host a conference call to discuss financial results that day beginning 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through t

    10/30/25 5:10:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Reports Second Quarter Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent Financial and Operating Highlights Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hyp

    8/18/25 4:10:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nyxoah SA

    SC 13D/A - Nyxoah SA (0001857190) (Subject)

    10/10/24 4:00:17 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Nyxoah SA (Amendment)

    SC 13D/A - Nyxoah SA (0001857190) (Subject)

    5/30/24 5:20:40 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Nyxoah SA (Amendment)

    SC 13G/A - Nyxoah SA (0001857190) (Subject)

    2/14/24 4:17:59 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care